A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Status:
Recruiting
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants
with breast cancer. The current cohort (Cohort 1) will focus on participants with inoperable,
locally advanced or metastatic, estrogen receptor (ER)-positive breast cancer who had disease
progression during or following treatment with a cyclin-dependent kinase 4/6 inhibitor
(CDK4/6i; e.g., palbociclib, ribociclib, abemaciclib) in the first- or second-line setting.
The study is designed with the flexibility to open new treatment arms as new treatments
become available, close existing treatment arms that demonstrate minimal clinical activity or
unacceptable toxicity, or modify the patient population.